Lonza Expands Florida Solid-Dose Facility

Published on: 

The expansion of Lonza’s Tampa site includes development and manufacturing capabilities for oral solid-dose drugs.

Lonza announced the completion of a $15-million multi-phase expansion of its oral solid-dose (OSD) development and manufacturing capabilities and capacity at its Tampa, FL site in a July 9, 2019 press release. The expansion will enable the Tampa site to provide more integrated services for customers across early-stage product development, clinical trial material manufacture, and commercialization of innovative drug products. The Tampa site is part of Lonza’s global network for the design, development, and manufacturing of drug substances and intermediates; particle engineering/bioavailability enhancement; and drug products for oral and inhaled applications.

As part of the multi-year investment, the site added a product development and quality control laboratory area with 13 processing suites. Two new packaging suites can support commercial packaging, including low-humidity environments and serialization for complete tracking and tracing of commercial products. Lonza also added new manufacturing suites and dedicated sampling and dispensing areas capable of handling highly potent compounds.

In addition, Lonza expanded and renovated the cGMP manufacturing cleanroom facility, as well as completely renovating 25,000 ftof the existing cGMP OSD manufacturing cleanroom facility.

The expansion included encapsulation and micro-dosing capabilities for Xcelodose Precision Powder Micro-Dosing Technology, Glatt GPCG-10 fluid bed processing, and Harro Hoefliger Modu-C capsule filling.


“This expansion at our Tampa site adds concept-to-commercial capacity for the US market. We continue to invest heavily in our site network to ensure that flexible, phase-appropriate and integrated capabilities are in place to meet the needs of today’s pharma and biotech innovator companies,” said Anthony Macci, senior vice-president of Global Operations, Chemical Division, Lonza Pharma & Biotech, in the press release. 

Source: Lonza